Atricure Stock Price, News & Analysis

AtriCure, Inc. (Nasdaq: ATRC) reported first quarter 2021 revenue of $59.3 million, an increase of 11.4% year-over-year. U.S. revenue grew 15.7% to $50.3 million, driven by increasing sales in key product categories, while international revenue declined 8.1% to $9 million due to COVID-19 restrictions. The gross profit rose to $44.5 million with a gross margin of 75.1%. The company reported a net loss of $15.9 million, or $0.38 per share, an improvement from $0.42 per share a year earlier. AtriCure projects full year 2021 revenue between $252 million and $256 million.

AtriCure, Inc. (Nasdaq: ATRC) has appointed B. Kristine Johnson as Board Chair. Scott Drake and Mark Lanning will not seek re-election in May 2021. Johnson, who has been on the board since 2017, is President of Affinity Capital Management and has extensive experience in the healthcare sector, including a 17-year career at Medtronic. Drake, who has served on AtriCure's Board since 2013, and Lanning, a board member since 2006, have both contributed significantly to the company's growth.

AtriCure, a leader in Afib treatments, will release its Q1 2021 financial results on April 27, 2021. The company will also host a conference call at 4:30 PM ET to discuss these results, accessible by calling (844) 884-9951 (domestic) or (661) 378-9661 (international), using conference ID 3349395. AtriCure is recognized for innovative solutions, including the FDA-approved Isolator Synergy Ablation System for persistent Afib and the widely used AtriClip Left Atrial Appendage Exclusion System.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Oppenheimer 31st Annual Healthcare Conference. The presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time. AtriCure offers innovative solutions, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, the most widely sold LAA management device globally. For more details, visit AtriCure's investor page.

AtriCure, Inc. (Nasdaq: ATRC) reported its fourth quarter and full year 2020 financial results, revealing a 5.9% decline in Q4 revenue to $57.7 million, with a full year revenue decrease of 10.5% to $206.5 million, attributed to COVID-19 impacts on surgical procedures. Gross profit in Q4 was $42.4 million with a margin of 73.5%. Adjusted EBITDA improved to a positive $1.7 million in Q4. For 2021, revenue guidance is projected at $250 million, with anticipated adjusted EBITDA losses of $10 million. The first quarter forecast revenue ranges from $55 million to $57 million.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 a.m. ET. The event will feature a live and archived audio webcast available on the company's website. AtriCure’s innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, are widely utilized for Afib treatment, impacting over 33 million individuals globally. For further details, visit AtriCure.com.

AtriCure, Inc. (Nasdaq: ATRC) will release its fourth quarter and full year 2020 financial results on February 23, 2021.

The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can join the call via phone or listen to a live audio webcast on AtriCure's corporate website. AtriCure specializes in innovative technologies for treating atrial fibrillation (Afib) and left atrial appendage (LAA) management, offering FDA-approved devices that lead the market.

AtriCure, Inc. (ATRC) announced its preliminary financial results for Q4 and full-year 2020, reporting revenue of approximately $57.7 million in Q4, a 6% decline year-over-year, and about $206.5 million for the full year, down 11%. The company acknowledged the impact of COVID-19 on procedure volumes but noted a sequential revenue increase of 5% from Q3 2020. AtriCure emphasized its strong financial position and strategic progress, highlighting upcoming catalysts for growth in 2021, including new procedures and clinical trial data.

AtriCure, Inc. (Nasdaq: ATRC) has announced FDA 510(k) clearance for expanded labeling claims of its cryo nerve block therapy, now including treatment for adolescent patients aged 12-21. The cryoICE® and cryoSPHERE™ probes provide effective pain management post-surgery, particularly for procedures like the Nuss procedure for pectus excavatum. Collaborating with the UCSF-Stanford Pediatric Device Consortium, AtriCure aims to innovate pediatric medical devices efficiently. This expansion could enhance recovery experiences for younger patients undergoing invasive chest wall surgeries.